万方数据
万方数据
万方数据
作者：邵蓉， 张子蔚， 常峰， Shao Rong， Zhang Ziwei， Chang Feng
作者单位：中国药科大学国际医药商学院，南京,211198 刊名：
中国药事
英文刊名：CHINESE PHARMACEUTICAL AFFAIRS
年，卷(期)：2009,23(8)
被引用次数：1次
参考文献(9条)
1.Mehta.Snyder Biosimilars Are Poised to Influence the Industry 2008
2.Huub Schellekens Follow-on biologics:challenges of the 'next generation' 2005(z 4)
3.Raines L J Bad medicine:why the generic drug regulatory paradigm is inapplicable to biotechnology products 2002
4.Schellekens H Bioequivalence and the immunogenicity of biopharmaceuticals 2002
5.Frank R Regulation of Follow-on Biologics 2007(09)
6.Mellstedt.Niederwieser.Ludwig The challenge of biosimilars 2008
7.Committee for Proprietary Medicinal Products.Guideline on Comparability of Medicinal Products Containing Biotechnology-derived Proteins as Active Substance.Non-clinical and Clinical
Issues.Evaluation of Medicines for Human Use,The European Agency for the 2003
8.Roger.Goldsmith Biosimilars:it's not as simple as cost alone 2008(05)
9.常卫红.王军志关于生物仿制药药学研究问题的思考 2008(01)
引证文献(1条)
1.姚颉靖.彭辉基于文献计量的药品专利保护统计分析[期刊论文]-华南理工大学学报（社会科学版） 2010(3)本文链接：d.g.wanfangdata/Periodical_zhonggys200908029.aspx
豫公网安备41160202000603
站长QQ:729038198
关于我们
投诉建议